Payment overview · 2025
General Payments
$1,673.52
83 reported records · 23 companies
Healthcare provider profile · identity verified
James Michael Isernia, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MYRTLE BEACH, SC · NPI 1144281148
Verified facts
What the public records show
CMS Open Payments records show James Michael Isernia, M.D. received $1,673.52 in general payments during 2025 across 83 reported records.
Novo Nordisk Inc accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $356.00 | 21.3% | 11 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $274.61 | 16.4% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $166.43 | 9.9% | 15 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $113.26 | 6.8% | 6 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $111.56 | 6.7% | 6 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $68.78 | 4.1% | 4 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $66.32 | 4.0% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $56.51 | 3.4% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $44.28 | 2.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.27 | 2.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.14 | 2.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.61 | 2.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.18 | 2.4% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $39.63 | 2.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.39 | 2.1% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $34.52 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.74 | 1.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $27.18 | 1.6% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $18.56 | 1.1% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $16.77 | 1.0% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $15.52 | 0.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.30 | 0.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.96 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,673.52 | 83 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $274.61 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $228.91 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $127.09 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $113.26 | 6 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $111.56 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $84.29 | 9 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $68.78 | 4 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $66.32 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $66.32 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $66.32 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.11 | 4 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $44.28 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.18 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $39.63 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.43 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.64 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $34.52 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $31.28 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.74 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.74 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.74 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $27.63 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $27.18 | 1 | 2025 |
Source payment records
|
|||||
| TERLIVAZ Normalized: terlivaz |
Drug | Mallinckrodt Hospital Products Inc. | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $13.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 124 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 170 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 151 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
104 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 42 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
124 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
170 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
151 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
162 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 805 | 251 |
| Levothyroxine Sodium | Levothyroxine Sodium | 629 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 580 | 189 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 553 | 176 |
| Lisinopril | Lisinopril | 427 | 137 |
| Omeprazole | Omeprazole | 422 | 141 |
| Losartan Potassium | Losartan Potassium | 406 | 130 |
| Metoprolol Succinate | Metoprolol Succinate | 399 | 130 |
| Pantoprazole Sodium | Pantoprazole Sodium | 390 | 133 |
| Gabapentin | Gabapentin | 334 | 117 |
| Alprazolam | Alprazolam | 291 | 58 |
| Metformin Hcl Er | Metformin Hcl | 287 | 92 |
| Escitalopram Oxalate | Escitalopram Oxalate | 253 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 244 | 80 |
| Pravastatin Sodium | Pravastatin Sodium | 225 | 69 |
| Simvastatin | Simvastatin | 213 | 58 |
| Trazodone Hcl | Trazodone Hcl | 211 | 63 |
| Allopurinol | Allopurinol | 210 | 56 |
| Furosemide | Furosemide | 195 | 76 |
| Montelukast Sodium | Montelukast Sodium | 194 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 188 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 73 |
| Famotidine | Famotidine | 170 | 59 |
| Mounjaro | Tirzepatide | 170 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 168 | 52 |
| Metformin Hcl | Metformin Hcl | 166 | 51 |
| Eliquis | Apixaban | 162 | 46 |
| Cefuroxime | Cefuroxime Axetil | 161 | 129 |
| Tramadol Hcl | Tramadol Hcl | 157 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 155 | 43 |
| Ozempic | Semaglutide | 151 | 32 |
| Lorazepam | Lorazepam | 150 | 39 |
| Methylprednisolone | Methylprednisolone | 146 | 126 |
| Celecoxib | Celecoxib | 142 | 47 |
| Sertraline Hcl | Sertraline Hcl | 139 | 45 |
| Donepezil Hcl | Donepezil Hcl | 132 | 34 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 130 | 39 |
| Pregabalin | Pregabalin | 128 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 43 |
| Jardiance | Empagliflozin | 124 | 42 |
| Bupropion Xl | Bupropion Hcl | 121 | 43 |
| Memantine Hcl | Memantine Hcl | 118 | 30 |
| Mirtazapine | Mirtazapine | 117 | 41 |
| Prednisone | Prednisone | 116 | 76 |
| Irbesartan | Irbesartan | 114 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 113 | 33 |
| Torsemide | Torsemide | 110 | 40 |
| Carvedilol | Carvedilol | 108 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 107 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 106 | 34 |
| Synthroid | Levothyroxine Sodium | 104 | 31 |
| Buspirone Hcl | Buspirone Hcl | 101 | 29 |
| Ezetimibe | Ezetimibe | 101 | 30 |
| Meloxicam | Meloxicam | 100 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 97 | 71 |
| Potassium Chloride | Potassium Chloride | 96 | 39 |
| Diazepam | Diazepam | 94 | 20 |
| Finasteride | Finasteride | 93 | 31 |
| Repaglinide | Repaglinide | 87 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 27 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 83 | 21 |
| Atenolol | Atenolol | 76 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 74 | 20 |
| Valsartan | Valsartan | 74 | 22 |
| Amoxicillin | Amoxicillin | 69 | 64 |
| Clonazepam | Clonazepam | 69 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 18 |
| Azithromycin | Azithromycin | 64 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 25 |
| Solifenacin Succinate | Solifenacin Succinate | 56 | 15 |
| Januvia | Sitagliptin Phosphate | 55 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 43 |
| Estradiol | Estradiol | 54 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 18 |
| Spironolactone | Spironolactone | 52 | 22 |
| Topiramate | Topiramate | 51 | 17 |
| Farxiga | Dapagliflozin Propanediol | 50 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 15 |
| Fluconazole | Fluconazole | 48 | 30 |
| Xarelto | Rivaroxaban | 47 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 46 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 14 |
| Valacyclovir | Valacyclovir Hcl | 46 | 17 |
| Mupirocin | Mupirocin | 45 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 13 |
| Cefdinir | Cefdinir | 43 | 36 |
| Fenofibrate | Fenofibrate | 41 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 19 |
| Methadone Hcl | Methadone Hcl | 41 | suppressed |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Glimepiride | Glimepiride | 40 | 16 |
| Azelastine Hcl | Azelastine Hcl | 39 | suppressed |
| Levofloxacin | Levofloxacin | 39 | 32 |
| Methylphenidate Hcl | Methylphenidate Hcl | 39 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 38 |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 23 |
| Ramipril | Ramipril | 36 | 13 |
| Temazepam | Temazepam | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | 14 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 35 | 11 |
| Acyclovir | Acyclovir | 34 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 29 |
| Ibuprofen | Ibuprofen | 34 | 16 |
| Ketoconazole | Ketoconazole | 33 | 15 |
| Nystatin | Nystatin | 33 | 19 |
| Tadalafil | Tadalafil | 33 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 12 |
| Rybelsus | Semaglutide | 30 | suppressed |
| Cholestyramine Light | Cholestyramine | 29 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 25 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Modafinil | Modafinil | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 18 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Dupixent Pen | Dupilumab | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Imvexxy | Estradiol | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,673.52 · 83 records | Novo Nordisk Inc | ABRYSVO, ACTHAR, AIRSUPRA, BREZTRI, Bimzelx, COMIRNATY, CRYSVITA, ENTRESTO, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, INJECTAFER, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, QUTENZA, REPATHA, REZDIFFRA, Rybelsus, TAVNEOS, TEPEZZA, TERLIVAZ, TREMFYA, TZIELD, Tymlos, UBRELVY, VRAYLAR, Wegovy, ZENPEP, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error